Non-alcoholic fatty liver disease (NAFLD) has been recognized as the most common liver disease and leading cause of cryptogenic cirrhosis worldwide (1, 2) . It includes a spectrum of hepatic dysfunctions ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), which causes liver cirrhosis (2) . Although the pathogenesis of NASH remains to be elucidated, NASH is thought to progress to liver cirrhosis and made potentially lead to hepatocellular carcinoma (3). Because the mechanism underlying the development of NAFLD has been linked to insulin resistance and an impairment of energy homeostasis, NAFLD is considered to be the hepatic manifestation of metabolic syndrome, which is reported to be a cluster of cardiovascular risk factors (2, 4, 5) .
Thyroid hormone plays an important role in energy homeostasis and influences body weight and lipid metabolism (6) . Hypothyroidism may cause of an impairment of energy homeostasis and induce hypercholesterolemia (7, 8) . Subclinical hypothyroidism, which refers to an elevated thyroid-stimulating hormone level and a normal free thyroxine (T4) level, has been associated with metabolic syndrome, cardiovascular disease and mortality (9, 10) . The relationship between NAFLD and hypothyroidism has also been reported. The prevalence of NAFLD is negatively correlated with free T4 levels, and decreased free T4 levels contribute to the risk of NAFLD (11) . Subclinical hypothyroidism has been found in NAFLD, and it has been reported that hypothyroidism is closely associated with NAFLD (12) .
On the other hand, little is known regarding the relationship between hyperthyroidism and NAFLD. In this issue of the journal, Miyake et al. reported a case of NASH with hyperthyroidism (13) . They showed the relationship between serum free T4 levels and serum alanine aminotransferase (ALT) levels in a patient with NASH complicated with Graves' disease. Three months after the commencement of thiamazole treatment, the patient's serum ALT levels and body weight increased concurrently with an improvement of abnormal thyroid hormone levels. The patient's body weight was 64.5 kg and body mass index (BMI) was 25.2 kg/m 2 at the commencement of thiamazole treatment. Eighteen months after the initial admission, the patient's body weight decreased to 53 kg and BMI to 20.7 kg, and the free T4 levels were increased and serum ALT levels fell to within normal levels. After the patient was diagnosed with reactivation of Graves' disease, thiamazole was resumed. As the thyroid hormone level decreased, the patient's serum ALT levels and body weight increased.
Interestingly, in this case, the patient's body weight and serum ALT levels appeared to have an inverse correlation with the serum free T4 levels. However, it remains unclear whether the serum free T4 levels are correlated with pathological staging and grading of NASH. A recent report indicated that the serum ALT level was not a candidate biomarker for NASH (14) . In particular, hepatic fibrosis progressed even in NASH patients with normal ALT levels (15) . Because the aspartate aminotransferase (AST)/ALT ratio is reported to be associated with hepatic fibrosis staging, the serum AST/ALT ratio is preferable as a potential hepatic fibrosis marker.
This manuscript presented that an anti-thyroid agent increased the serum ALT levels in a NASH patient with Graves' disease. An accumulation of case reports of NASH complicated with hyperthyroidism is expected, and it is of particular interest to examine whether thyroid hormone or its analogue improves NASH as a new strategy for the regulation of steatohepatitis.
